Acellular mucin in lymph nodes isolated from treatment-naïve colorectal cancer resections: a clinicopathologic analysis of 16 cases
- PMID: 35513610
- PMCID: PMC9979094
- DOI: 10.1007/s00428-022-03332-5
Acellular mucin in lymph nodes isolated from treatment-naïve colorectal cancer resections: a clinicopathologic analysis of 16 cases
Abstract
Lymph nodes with acellular mucin harvested from treated colorectal cancers (CRC) are staged as pN0. However, there is variability among pathologists while reporting the pN stage when acellular mucin is found within nodes of untreated CRCs. While the UICC guidelines suggest staging them as pN1, the AJCC and CAP do not offer any recommendations. In order to characterize their clinicopathologic features and outcome, we compared 16 untreated CRCs (study group; mean age: 68 years) harboring nodes with acellular mucin with 34 pN0 and 25 pN1 untreated CRC controls. All tumors were unifocal; 12 (75%) were right-sided lesions. Most cases (75%) showed one node with acellular mucin (range: 1-3). MMR-deficient tumors were significantly more common in the study group (83%) compared to pN0 (33%; p = 0.006) and pN1 controls (8%; p < 0.001). The overall survival of study group patients was closer to pN0 compared to pN1 controls; however, this difference was not statistically significant. In conclusion, untreated CRC that harbor acellular mucin within lymph nodes commonly present as right-sided, MMR-deficient tumors in older women that show a non-mucinous phenotype. While the limited number of cases precludes us from making any formal recommendations about staging, we suggest that the finding of acellular mucin in a node should prompt evaluation of deeper levels (with or without cytokeratin immunohistochemistry) and submission of all pericolonic fat for additional lymph node harvest. Whether acellular mucin in nodes of untreated CRCs is related to the indolent biology of the disease, a robust local immune response or MMR deficiency requires further investigation.
Keywords: Acellular mucin; Colon cancer; Lymph nodes; Untreated.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
DECLARATIONS:
Safety Monitoring Board or Advisory Board - Bayer, BMS, Janssen; Medical and Scientific Advisory Board, NBCA (unpaid).
All remaining authors have no conflicts of interest.
Figures


Similar articles
-
Clinicopathologic Features of Untreated Colorectal Cancer with Acellular Mucin-Only Lymph Nodes.Mod Pathol. 2025 Jun 11;38(10):100811. doi: 10.1016/j.modpat.2025.100811. Online ahead of print. Mod Pathol. 2025. PMID: 40513988
-
Additional lymph node examination from entire submission of residual mesenteric tissue in colorectal cancer specimens may not add clinical and pathologic relevance.Hum Pathol. 2007 May;38(5):762-7. doi: 10.1016/j.humpath.2006.11.005. Epub 2007 Feb 15. Hum Pathol. 2007. PMID: 17306331
-
How do we stage acellular mucin in lymph nodes of colorectal cancer specimens without neo-adjuvant therapy?Histopathology. 2016 Sep;69(3):527-8. doi: 10.1111/his.12970. Epub 2016 May 5. Histopathology. 2016. PMID: 26993265 No abstract available.
-
Serosal surfaces, mucin pools, and deposits, oh my: challenges in staging colorectal carcinoma.Mod Pathol. 2015 Jan;28 Suppl 1:S95-108. doi: 10.1038/modpathol.2014.128. Mod Pathol. 2015. PMID: 25560604 Review.
-
Lymph node revealing solutions in colorectal cancer: should they be used routinely?J Clin Pathol. 2014 May;67(5):383-8. doi: 10.1136/jclinpath-2013-202146. Epub 2014 Feb 3. J Clin Pathol. 2014. PMID: 24493650 Review.
Cited by
-
Acellular mucin in neoplastic and non-neoplastic conditions of the lower gastrointestinal tract.World J Gastrointest Surg. 2025 Jul 27;17(7):106672. doi: 10.4240/wjgs.v17.i7.106672. World J Gastrointest Surg. 2025. PMID: 40740892 Free PMC article. Review.
References
-
- Haller DG, Catalano PJ, Macdonald JS, O’Rourke MA, Frontiera MS, Jackson DV, Mayer RJ (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089 J Clin Oncol 23:8671–8678. doi: 10.1200/JCO.2004.00.5686 - DOI - PubMed
-
- Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, Zheng Y, Green E, Labianca R, O’Callaghan C, Seitz JF, Francini G, Haller D, Yothers G, Goldberg R, de Gramont A (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials J Clin Oncol 27:872–877. doi: 10.1200/JCO.2008.19.5362 - DOI - PMC - PubMed
-
- Jessup JM, Goldberg RM, Asare EA, et al. (2017) Colon and Rectum. In: Amin MB (ed) AJCC Cancer Staging Manual, 8th.edn. Springer, Chicago (IL), pp. 251–274
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous